Handelsbanken Fonder AB Has $14.34 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Handelsbanken Fonder AB decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 55.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 74,898 shares of the biopharmaceutical company’s stock after selling 94,845 shares during the quarter. Handelsbanken Fonder AB’s holdings in Alnylam Pharmaceuticals were worth $14,336,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd lifted its position in Alnylam Pharmaceuticals by 69.1% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after acquiring an additional 77,307 shares in the last quarter. Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after acquiring an additional 30,608 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Alnylam Pharmaceuticals by 630.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after acquiring an additional 22,580 shares in the last quarter. Asset Management One Co. Ltd. lifted its position in shares of Alnylam Pharmaceuticals by 41.3% during the 4th quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock worth $13,569,000 after buying an additional 20,268 shares in the last quarter. Finally, Royal London Asset Management Ltd. lifted its position in shares of Alnylam Pharmaceuticals by 86.7% during the 3rd quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock worth $54,303,000 after buying an additional 142,357 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $146.07 on Wednesday. The company has a fifty day moving average price of $151.09 and a 200-day moving average price of $166.50. The firm has a market capitalization of $18.40 billion, a P/E ratio of -41.03 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $143.50 and a one year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. During the same quarter last year, the firm earned ($1.68) earnings per share. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on ALNY shares. Chardan Capital dropped their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Citigroup dropped their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Finally, The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Nine analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.